A Phase II Clinical Study of SYH2068 Injection in Adults With Elevated Lipoprotein(a)

Inclusion Criteria: 1. Male or female participants ≥18 years of age; 2. Elevated Lp(a); 3. Participants who have used lipid-lowering drugs continue to use a stable dose, and those who have not used do not start new lipid-lowering drugs; 4. Presence of ASCVD or ASCVD risk stratification assessed as moderate or high risk; 5. Participants are able to understand and cooperate to complete this study, voluntarily participate in this study, and sign the ICF. Exclusion Criteria: 1. Diseases that significantly affect Lp(a) during screening period, 2. Major or unstable cardiovascular events occurring from 3 months before signing the ICF to randomization; 3. Undergoing or expected to undergo peripheral arterial, coronary, or cerebrovascular revascularization surgery or other major surgery within 3 months prior to signing the ICF until randomization or during the study period; 4. NYHA class III-IV at the time of signing the ICF or LVEF \<40% during the screening period; 5. Type 1 diabetes or hereditary hemorrhagic disorder at screening; 6. History of malignant tumor or suspected malignancy within 5 years prior to screening; 7. Use of drugs affecting Lp(a) within the specified period before screening or expected to use during the study period; 8. Allergy to oligonucleotide drugs; 9. Received any other clinical study treatment within 3 months prior to screening or within 5 half-lives of the investigational drug; 10. Female participants who are pregnant or breastfeeding at screening, or female / male participants who plan to conceive during the study and within 1 year after the last dose.